{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Computational chemistry", "Drug design", "Drug development", "Drug-protein interactions", "KasA inhibitor", "Ligand efficiency", "M. tuberculosis", "Malawi", "Medicinal Chemistry", "\u03b2-ketoacyl-ACP synthase"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37215382", "DateRevised": {"Year": "2023", "Month": "05", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "12"}], "Language": ["eng"], "ELocationID": ["10.1016/j.sciaf.2021.e00824"], "Journal": {"ISSN": "2468-2276", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2021", "Month": "Jul"}}, "Title": "Scientific African", "ISOAbbreviation": "Sci Afr"}, "ArticleTitle": "Ligand-protein interactions of plant-isolated (9z,12z)-octadeca-9,12-dienoic acid with \u0392-ketoacyl-Acp synthase (KasA) in potential anti-tubercular drug designing.", "Pagination": {"StartPage": "e00824", "MedlinePgn": "e00824"}, "Abstract": {"AbstractText": ["Mycobacterium tuberculosis remains one of the world's contributors to mortality. With the emergence of SARS-CoV-2 coinfections, patients with TB are predisposed to being more heavily weighed down by COVID-19 disease and its opportunistic coinfections. The severity of the disease coupled with drug resistance on the currently used drugs warrants for the search for alternative remedies from synthetic agents, semisynthetics and natural products that include plants. Africa is rich in plant diversity with a promise as sources of drug agents, one of which is <i>Eichhornia crassipes</i>. This work aimed at isolating a fatty acid and dock it to \u03b2-ketoacyl-ACP synthase for possible anti-TB drug development prospects using computational tools. (9z,12z)-Octadeca-9,12-dienoic acid was isolated from <i>Eichhornia crassipes</i> for the first time using chromatographic techniques and identified using 1D and 2D NMR spectroscopic methods (<sup>1</sup>H NMR, COSY, HSQC, HMBC and <sup>13</sup>C NMR). The compound was then docked to \u03b2-ketoacyl-ACP synthase (KasA), an essential member of the b-ketoacyl synthases encoded in the <i>M. tuberculosis</i> genome in comparison with its co-crystallized ligand JSF-3285, also for the first time. (9z,12z)-Octadeca-9,12-dienoic acid interacted with only phenylalanine239 and proline201 while JSF-3285 interacted with proline201, glutamine120, alanine119, leucine116, glutamine199, histadine345, phenylalanine239, glycine240 and glycine200. (9z,12z)-Octadeca-9,12-dienoic acid had a ligand efficiency of 0.24, compared to the co-crystallized ligand's 0.36. The compound was too flexible and elongated with -4.72 KCalmol<sup>-1</sup> binding energy. Despite some unfavourable physico-chemical properties, the compound still provides reliable interactions that only require logical structural modifications by the addition of polar regions amongst others to increase interactions and ligand efficiency, which can consequently stand to be a better potential drug lead. For the first time, plant-based (9z,12z)-Octadeca-9,12-dienoic acid isolated from <i>Eichhornia crassipes</i> was shown to interact fairly well with \u03b2-ketoacyl-ACP synthase and proved to be a potential starting material from which anti-tubercular drugs can be designed."], "CopyrightInformation": "\u00a9 2021 The Authors."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Section, Department of Applied Studies, Institute of Technology, Malawi University of Science and Technology, Malawi."}, {"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Mtewa", "ForeName": "Andrew G", "Initials": "AG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Kamuzu University of Health Sciences, Blantyre, Malawi."}, {"Identifier": [], "Affiliation": "Africa Centre of Excellence in Public Health and Herbal Medicine (ACEPHEM), Kamuzu University of Health Sciences, Malawi."}], "LastName": "Bvunzawabaya", "ForeName": "Jonathan T", "Initials": "JT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Chemistry, Institute of Molecular Science, University of Witwatersrand, South Africa."}], "LastName": "Ngwira", "ForeName": "Kennedy J", "Initials": "KJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical Sciences, Kamuzu University of Health Sciences, Blantyre, Malawi."}, {"Identifier": [], "Affiliation": "Africa Centre of Excellence in Public Health and Herbal Medicine (ACEPHEM), Kamuzu University of Health Sciences, Malawi."}], "LastName": "Lampiao", "ForeName": "Fanuel", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biotechnology Section, Centre for Chemistry and Chemical Engineering, Lund University, Lund, Sweden."}, {"Identifier": [], "Affiliation": "Marian University College, Department of Biological and Marine Sciences, Bagamoyo, Tanzania."}], "LastName": "Maghembe", "ForeName": "Reuben", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Okella", "ForeName": "Hedmon", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Weisheit", "ForeName": "Anke", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Tolo", "ForeName": "Casim U", "Initials": "CU"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Ogwang", "ForeName": "Patrick E", "Initials": "PE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmbiotechnology and Traditional Medicine Centre (PHARMBIOTRAC), Mbarara University of Science and Technology, Mbarara, Uganda."}], "LastName": "Sesaazi", "ForeName": "Duncan C", "Initials": "DC"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Sci Afr", "NlmUniqueID": "101771789", "ISSNLinking": "2468-2276"}, "CoiStatement": "The authors declare no conflict of interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Marimuthu Y., et al. COVID-19 and tuberculosis: a mathematical model based forecasting in Delhi, India. Indian J. Tuberc. 2020;67(2):177\u2013181.", "ArticleIdList": ["PMC7214306", "32553309"]}, {"Citation": "Falzon D., et al. Vol. 49. WHO; Geneva: 2017. (World Health Organization Treatment Guidelines For Drug-Resistant tuberculosis, 2016 Update).", "ArticleIdList": ["PMC5399349", "28331043"]}, {"Citation": "Choi W.H. Evaluation of anti-tubercular activity of linolenic acid and conjugated-linoleic acid as effective inhibitors against Mycobacterium tuberculosis. Asian Pac. J. Trop. Med. 2016;9(2):125\u2013129.", "ArticleIdList": ["26919940"]}, {"Citation": "Banerjee Amitava, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. The Lancet. 2020;395(10238):1715\u20131725.", "ArticleIdList": ["PMC7217641", "32405103"]}, {"Citation": "He G., et al. COVID-19 in tuberculosis patients: a report of three cases. J. Med. Virol. 2020 n/a(n/a)", "ArticleIdList": ["PMC7267258", "32343410"]}, {"Citation": "Crisan-Dabija R., et al. Tuberculosis and COVID-19: lessons from the past viral outbreaks and possible future outcomes. Canadian Respiratory Journal. 2020;(Article ID 1401053):1\u201311. doi: 10.1155/2020/1401053.", "ArticleIdList": ["10.1155/2020/1401053", "PMC7479474", "32934758"]}, {"Citation": "Guan W.J., et al. Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis.European. Respiratory Journal. 2020;55(5)", "ArticleIdList": ["PMC7098485", "32217650"]}, {"Citation": "Liu, Yongyu, et\u00a0al. Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. MedRxiv (2020). Page 1. doi: 10.1101/2020.03.10.20033795", "ArticleIdList": ["10.1101/2020.03.10.20033795"]}, {"Citation": "Kim H.Y., et al. Thoracic sequelae and complications of tuberculosis. radiographics. 2001;21(4):839\u2013858.", "ArticleIdList": ["11452057"]}, {"Citation": "Gupta U.D., Katoch V.M., McMurray D.N. Current status of TB vaccines. Vaccine. 2007;25(19):3742\u20133751.", "ArticleIdList": ["17321015"]}, {"Citation": "Sierra V.G. Is a new tuberculosis vaccine necessary and feasible? A Cuban opinion. Tuberculosis. 2006;86(3\u20134):169\u2013178. (Edinb.)", "ArticleIdList": ["16677860"]}, {"Citation": "Okada M. [Novel vaccines against M. tuberculosis] Kekkaku. 2006;81(12):745\u2013751.", "ArticleIdList": ["17240920"]}, {"Citation": "Ingolotti M., et al. DNA vaccines for targeting bacterial infections. Expert Rev. Vaccines. 2010;9(7):747\u2013763.", "ArticleIdList": ["PMC2962930", "20624048"]}, {"Citation": "Caminero J.A., et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet; Infectious diseases. 2010;10(9):621\u2013629.", "ArticleIdList": ["20797644"]}, {"Citation": "Zhang Y., Disease W.W Yew. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. International Journal of Tuberculosis and Lung Disease. 2015;19(11):1276\u20131289.", "ArticleIdList": ["26467578"]}, {"Citation": "Swain S.S., et al. Isoniazid\u2013phytochemical conjugation: a new approach for potent and less toxic anti-TB drug development. Chem. Biol. Drug Des. 2020;96(2):714\u2013730. n/a(n/a)", "ArticleIdList": ["32237023"]}, {"Citation": "Slayden R.A., Barry C.E. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis. Tuberculosis. 2002;82(4\u20135):149\u2013160. (Edinb.)", "ArticleIdList": ["12464486"]}, {"Citation": "Abrahams K.A., et al. Identification of KasA as the cellular target of an anti-tubercular scaffold. Nat. Commun. 2016;7:12581.", "ArticleIdList": ["PMC5025758", "27581223"]}, {"Citation": "Mdluli K., et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science. 1998;280(5369):1607\u20131610.", "ArticleIdList": ["9616124"]}, {"Citation": "Inoyama D., et al. A preclinical candidate targeting mycobacterium tuberculosis KasA. Cell Chem. Biol. 2020;27(5):560\u2013570. e10.", "ArticleIdList": ["PMC7245553", "32197094"]}, {"Citation": "Jethva K.D., Bhatt D.R., Zaveri M.N. Antimycobacterial screening of selected medicinal plants against Mycobacterium tuberculosis H37Rv using agar dilution method and the microplate resazurin assay. International Journal of Mycobacteriology. 2020;9(2):150.", "ArticleIdList": ["32474536"]}, {"Citation": "Nirmal C.R., et al. Anti-tuberculosis activity of bio-active compounds from Lantana camara L., Euphorbia hirta L., Mukia maderaspatana (L.) M. Roem, and Abutilon indicum (L.) European Journal of Integrative Medicine. 2020;35:101105."}, {"Citation": "Nimbeshaho F., et al. Antimycobacterial activities, cytotoxicity and phytochemical screening of extracts for three medicinal plants growing in Kenya. J. Med. Plants Res. 2020;14(4):129\u2013143."}, {"Citation": "Ekundayo E., Kalu U, Enya E. In-vitro inhibitory activity of extracts of some medicinal plants against Mycobacte-rium smegmatis. NJM. 2020;34(1):5044\u20135052."}, {"Citation": "Verma Devvret, et al. Medicinal plant of Uttarakhand (India) and their benefits in the treatment of tuberculosis: current perspectives. Global Journal of Bio-Science and Biotechnology. 2020;9(3):75\u201385."}, {"Citation": "C\u00e1ceres M., et al. Essential oils of aromatic plants with antibacterial, anti-biofilm and anti-quorum sensing activities against pathogenic bacteria. Antibiotics. 2020;9(4):147.", "ArticleIdList": ["PMC7235784", "32235590"]}, {"Citation": "Mtewa A., Sesaazi D.C., Lampiao F. Structural and in silico characterization of small molecules isolated from eichhornia crassipes. J Evid. Based Complement. Altern. Med. 2020;2020(Article ID 1375639):1\u201314. doi: 10.1155/2020/1375639.", "ArticleIdList": ["10.1155/2020/1375639", "PMC7246410", "32508941"]}, {"Citation": "Ferreira L.G., et al. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384\u201313421.", "ArticleIdList": ["PMC6332083", "26205061"]}, {"Citation": "Morris G.M., et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30(16):2785\u20132791.", "ArticleIdList": ["PMC2760638", "19399780"]}, {"Citation": "Morris G.M., Huey R., Olson A.J. Using Autodock for ligand-receptor docking. Curr. Protoc. Bioinform. 2008:8\u201314. doi: 10.1002/0471250953.bi0814s24. Chapter 8: Unit 8.14.", "ArticleIdList": ["10.1002/0471250953.bi0814s24", "19085980"]}, {"Citation": "Yuan S., Chan H.S., Hu Z. Using PyMOL as a platform for computational drug design.WIREs. Comput Mol Sci. 2017;7(2):e1298."}, {"Citation": "Biovia D., et al. Vol. 10. Dassault Syst\u00e8mes; San Diego: 2000. (Dassault Syst\u00e8mes BIOVIA, Discovery Studio Visualizer, v. 17.2). 2016p. 0021-9991."}, {"Citation": "NCBI  . National Center for Biotechnology Information; 2020. PubChem Compound Summary For CID 5280934, Linolenic Acid.https://pubchem.ncbi.nlm.nih.gov/compound/Linolenic-acid p."}, {"Citation": "Fileto-P\u00e9rez H.A., et al. GC/MS analysis of some extractives from eichhornia crassipes. 2015.BioResources. 2015;10(4):7353\u20137360."}, {"Citation": "Kumar P., et al. Synergistic lethality of a binary inhibitor of mycobacterium tuberculosis KasA. mBio; American Society for Microbiology. 2018;9(6)", "ArticleIdList": ["PMC6299220", "30563908"]}, {"Citation": "McFarland C.T., et al. Dietary polyunsaturated fatty acids modulate resistance to Mycobacterium tuberculosis in guinea pigs. J. Nutr. 2008;138(11):2123\u20132128.", "ArticleIdList": ["PMC2635522", "18936208"]}, {"Citation": "Chandra P., et al. Inhibition of fatty acid oxidation promotes macrophage control of mycobacterium tuberculosis. mBio; American Society for Microbiology. 2020;11(4)", "ArticleIdList": ["PMC7343992", "32636249"]}, {"Citation": "Mali J.K., et al. Novel fatty acid-thiadiazole derivatives as potential antimycobacterial agents. Chemical Biology and Drug Design. 2020;95(1):174\u2013181.", "ArticleIdList": ["31581353"]}, {"Citation": "Agarwal P., et al. Foam Cells Control Mycobacterium tuberculosis Infection. Frontiers in microbiology. 2020;11:1394.", "ArticleIdList": ["PMC7381311", "32754123"]}, {"Citation": "Kumar T., et al. Fatty acids-carotenoid complex: an effective anti-TB agent from the chlorella growth factor-extracted spent biomass of Chlorella vulgaris. J Ethnopharmacol. 2020;249:112392.", "ArticleIdList": ["31739107"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "12", "Day": "9"}, {"Year": "2021", "Month": "4", "Day": "23"}, {"Year": "2021", "Month": "6", "Day": "4"}, {"Year": "2021", "Month": "7", "Day": "1", "Hour": "0", "Minute": "1"}, {"Year": "2021", "Month": "7", "Day": "1", "Hour": "0", "Minute": "0"}, {"Year": "2023", "Month": "5", "Day": "22", "Hour": "12", "Minute": "25"}, {"Year": "2021", "Month": "6", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37215382", "PMC10190923", "10.1016/j.sciaf.2021.e00824", "S2468-2276(21)00128-9"]}}], "PubmedBookArticle": []}